Please assess the completion status of the following clinical trial:

Trial Title: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Is a premenopausal female aged 18 to 50 years old (inclusive) on the day of signing of the informed consent form.~2. Has agreed to use only study-specified analgesic medications during the study and is not known to be intolerant to these.~3. Has a diagnosis of endometriosis and has had, within 10 years prior to signing the informed consent form, surgical or direct visualization and/or histopathologic confirmation of endometriosis, for example, during a laparoscopy or laparotomy.~4. During the Run-In Period (35 to 70 days prior to treatment period) has a dysmenorrhea NRS score ≥ 4.0 on at least 2 days and~   1. Mean NMPP NRS score ≥ 2.5, or~  2. Mean NMPP NRS score ≥ 1.25 and NMPP NRS score ≥ 5.0 on ≥ 4 days.~Key Exclusion Criteria:~1. Has a history of chronic pelvic pain that is not caused by endometriosis.~2. Has any chronic pain or frequently recurring pain condition, other than endometriosis that is treated with opioids or requires analgesics for ≥ 7 days per month.~3. Has had surgical procedures for treatment of endometriosis within the 3 months prior to the Screening visit.~4. Has a history of or currently has osteoporosis or other metabolic bone disease.~5. Has a clinically significant gynecologic condition, other than endometriosis, identified during Screening or Run-In period transvaginal ultrasound or endometrial biopsy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Group A) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA for 24 weeks.
- Relugolix plus Delayed E2/NETA (Group B) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
- Placebo (Group C) (Type: PLACEBO_COMPARATOR): Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).